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Abstract
Background: Dyspepsia is a common disorder in the community, with many patients referred for
diagnostic gastroscopy by their General Practitioner (GP). The National Institute of Clinical
Excellence (NICE) recommends follow-up after investigation for cost effective management,
including lifestyle advice and drug use. An alternative strategy may be the use of a gastro-intestinal
nurse practitioner (GNP) instead of the GP. The objective of this study is to compare the
effectiveness and costs of systematic GNP led follow-up to usual care by GPs in dyspeptic patients
following gastroscopy.
Results:  Direct access adult dyspeptic patients referred for gastroscopy; without serious
pathology, were followed-up in a structured nurse-led outpatient clinic. Outcome measurement
used to compare the two study cohorts (GNP versus GP) included Glasgow dyspepsia severity
(Gladys) score, Health Status Short Form 12 (SF12), ulcer healing drug (UHD) use and costs. One
hundred and seventy five patients were eligible after gastroscopy, 89 were randomised to GNP
follow-up and 86 to GP follow-up. Follow-up at 6 months was 81/89 (91%) in the GNP arm and 79/
86 (92%) in the GP arm. On an intention to treat analysis, adjusted mean differences (95%CI) at
follow-up between Nurse and GP follow-up were: Gladys score 2.30 (1.4–3.2) p < 0.001, SF12
140.6 (96.5–184.8) p =< 0.001 and UHD costs £39.60 (£24.20–£55.10) p =< 0.001, all in favour of
nurse follow-up.
Conclusion: A standardised and structured follow-up by one gastrointestinal nurse practitioner
was effective and may save drug costs in patients after gastroscopy. These findings need replication
in other centres.
Background
Dyspepsia is a common complaint that leads to signifi-
cant health care costs [1-3]. The management of dyspepsia
and its related causes has progressed in recent years. In
England, the National Institute of Clinical Excellence
(NICE), published recommendations (2004) to promote
cost effective management [4]. Key recommendations
were for follow-up, after direct access gastroscopy to
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maintain minimum effective therapy, to provide lifestyle
advice and to perform an annual review. A large propor-
tion of these patients are managed within primary care
but the effectiveness of such care is unknown [5]. A con-
tributory factor may be the limited time of a general prac-
titioner's (GP) consultation and prioritisation of GP
workload to more serious conditions. Other health-care
professionals, such as gastrointestinal nurse practitioners
(GNP), may be capable of taking on this role and provide
more appropriate care within available resources.
This study describes a randomised controlled trial, which
compared the effectiveness and impact on acid suppres-
sant use and costs of a systematic GNP-led follow-up in an
outpatient clinic to usual care by GPs, in patients with dys-
pepsia after direct access gastroscopy.
Methods
All GP surgeries in the catchment area of a teaching hospi-
tal referral centre (Southampton University Hospital
Trust) were included. All direct access referrals for gastros-
copy were screened to exclude those with sinister symp-
toms i.e. dysphagia, vomiting, anaemia, rapid weight loss
or those with history of gastric surgery. Patients were con-
sented at the point of recruitment. Trained medical endo-
scopists performed the gastroscopy procedure. Patients
found to have peptic ulcer, tumour, severe oesophagitis
(grade C and D), Barrett's oesophagus and anatomical
abnormality were excluded. Patients included were those
with mild gastro-oesophageal reflux disease (GORD –
non-erosive or grade A and B oesophagitis, hiatus hernia),
non-ulcer dyspepsia (NUD) (mild and moderate gastritis
or duodenitis) and those with normal findings.
Baseline details of socio-demographic factors, education,
self-reported height and weight, smoking, alcohol (cur-
rent versus non-drinker) and ulcer healing drugs (UHD)
used in the past 6 months were collected by interview of
all patients presenting for elective gastroscopy at South-
ampton University Hospitals Trust for the period between
May 2002 to May 2004. All patients also completed two
validated questionnaires relating to the past 6 months: the
Glasgow Dyspepsia severity scores (Gladys) and the
Health Status Short Form 12 (SF-12) [6,7]. After gastros-
copy, endoscopists maintained their routine practice in
giving verbal and written advice to patients and docu-
mented treatment recommendation to GPs in a formal
report. Patients eligible for entry after endoscopy were
randomised into intervention (GNP) and control (GP)
groups, with a password protected, computer generated
random number table. The endoscopists telephoned a
separate office to obtain the follow-up status. The 'GNP'
group was given one out-patient appointment. The 'GP'
cohort was discharged and advised to see their GP.
In the nurse-led clinic, a full medical history was taken.
The clinical management was structured, based on
national and local guidelines, with reference to each
patient's predominant symptoms. Patients were given
counselling and lifestyle advice, supplemented with rele-
vant locally devised leaflets i.e. reflux, non-ulcer dyspep-
sia, weight control, and an individualised treatment plan
agreed with them. Further investigation such as the urea
breath test, motility studies and barium meal were initi-
ated if required, as per routine clinical practice. To ensure
practice consistency and reproducibility, 'history taking'
and 'lifestyle advice' proformas were devised and used.
Follow-up
A researcher blinded to the patients' study status and diag-
nosis, interviewed all participants by telephone, at a pre-
arranged time suitable to the patient, six months after ran-
domisation. Data collected were Gladys dyspepsia score,
SF-12 score, self-reported UHD used and weight and a
patient satisfaction questionnaire.
Drug use and cost
The use of UHDs for the six months before (baseline) and
for 6 months after trial entry were summed and averaged
according to class: Proton pump inhibitors (PPI) and
Histamine2  receptor antagonists (H2RA) and strength
(half and full-dose PPI). Half-dose PPI and H2RAs were
grouped, as they were equivalent in costs. Drug use by
month, based on quantity of tablets, was therefore
grouped: 'full-dose PPI' vs 'half-dose PPI and H2RA' vs 'no
treatment'. Twice daily full-dose PPI was counted as 2
months and alternate days use counted as half a month.
On demand therapy was recorded according to number of
tablet/s taken per week and multiplied by 4 to give a
monthly quantity. UHD prices were taken for each spe-
cific UHD from Monthly Index of Medical Speciality
(MIMS 2006) and Drug Tariff (2006).
Statistical analysis
A sample size calculation indicated that a minimum of
186 patients, 93 in each group, would be needed to detect
a 1 point of improvement on the Gladys dyspepsia scale
with 80% power at the 5% significance level. This calcula-
tion was based on a standard deviation of 2.85 that came
from a pilot study of 30 cases presenting for gastroscopy
in which the Gladys scores were obtained before the pro-
cedure.
The two groups were compared by the change from base-
line to month 6 in the key outcome variables – Gladys
score, SF12 and overall UHDs cost, adjusted for baseline
values by including the baseline levels of the outcome in
the ANOVA as a covariate; p < 0.05 was taken as being sig-
nificant. Intention to treat analysis was undertaken by
assuming the 15 patients with no 6 month follow-up data
did not change from baseline. The component scales of
SF12 and Gladys were analysed with p values calculated
using the Mann-Whitney or Chi-square test where appro-BMC Gastroenterology 2009, 9:12 http://www.biomedcentral.com/1471-230X/9/12
Page 3 of 8
(page number not for citation purposes)
priate; a p value of < 0.01 was taken because of multiple
testing.
Local ethics committee approval was obtained (reference
no. 050-02) and the study registered with the Southamp-
ton University Hospitals NHS Trust Research Department.
Results
Over a 2 year period, on the elective direct access gastros-
copy lists at which the GNP could attend, 199 unselected
patients were approached and 196 (98.5%) were
recruited. One hundred and seventy five (89.3%) patients
were eligible after investigation. Of the 21 ineligible
patients, 16 did not meet the criteria (Barrett's oesopha-
gus: 6, oesophagitis grade C: 2, oesophageal stricture: 1,
peptic ulcer disease: 3, possible cancer: 1). Three cases
were deemed unsuitable by the endoscopist, as symptoms
were attributed to other conditions (rhinitis 1, angina 2).
Two did not have the procedure (failed intubation 1, food
in stomach 1).
The 175 patients were randomised, 86 to GP follow-up
(GP) and 89 to nurse follow-up (GNP). There were no
obvious differences in the baseline characteristics of the
two groups in age, BMI, smoking, alcohol and education
status (see Table 1). The baseline Gladys scores (high
scores equal higher burden of disease and symptoms)
were similar (10.0 vs 9.9) but the SF12 scores (672.0 vs
627.7) were higher (high scores equal better health) in the
GP group (see Table 1). The cost of UHD used, 6 months
prior to the investigation, was lower in the GP group
(£52.4 vs £59.5).
Intervention
Early withdrawals (GP n = 3 GNP n = 4) after randomisa-
tion were experienced in both groups (Figure 1), Three in
the 'GP' group decided not to see their GP. The four in the
Table 1: Baseline characteristics of patients randomised to 'GP' and 'GNP' groups.
Treatment group
GP
N = 86
GNP
N = 89
Age yrs Mean (SD) 48.4(12.8)) 50.2 (13.9)
Gender Male 42 (49) 44 (49)
BMI kg/m2 Mean (SD) 27.5 (5.0) 27.0 (5.8)
Smoking status Current 23 (27) 24 (27)
Ex 43 (50) 42 (47)
Non 19 (22) 23 (26)
Unknown 1 (1) 0 (0)
Alcohol Drinker 76(88) 78 (88)
Education (grouping)
No qualifications 30 (35) 35 (39)
'O' levels & vocational qualifications 22 (26) 20 (22)
'A' levels to diplomas 11 (13) 12 (13)
Professional, 1st & higher degrees 23 (27) 22 (25)
Gladys score Mean (SD) 10.0 (3.0) 9.9 (3.2)
SF12 Mean (SD) 672.0 (157.3) 627.7 (197.930)
UHD costs (based on following*) Mean (SD) in £ 52.4(47.6) 59.5(46.3)
*UHD types in previous 6 months Months of use
Full dose PPI 1.4(2.0) 1.5(2.0)
Half dose PPI or H2RA 1.1(1.9) 1.5(2.2)
None 3.4(2.2) 3.0(2.2)
* Details of grouping in 'Statistical analysis'.
Figures are number (%) unless specified.BMC Gastroenterology 2009, 9:12 http://www.biomedcentral.com/1471-230X/9/12
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'GNP' group were due to work commitments (2), leaving
the area (1) and after own GP consultation (1). 78/89
(88%) actually attended the GNP clinic compared to only
40/86 (47%) in the GP arm.
In the GP arm, 12 (30.0%) recalled not having had their
gastroscopy findings explained, 23 (57.5%) were given
lifestyle advice and 5 (12.5%) received dyspepsia infor-
mation leaflets by their GPs. Most patients found the
information given to them of limited use and most of
them rated it ineffective in changing their lifestyle. In con-
trast, all those who attended the nurse-led clinic said that
their gastroscopy findings were explained and receiving
lifestyle advice with leaflets. Furthermore, most patients
reported that this information enabled them to make pos-
itive lifestyle changes.
6 month follow-up
The response rate was high: 79/86 (92%) in the GP arm
and 81/89 (91%) patients in the GNP arm (see Figure 1).
Both groups had symptom improvement at 6 month fol-
low-up but this was significantly better in the 'GNP' group
(see Table 2) showing the Gladys score difference adjusted
for baseline was 2.3 (1.4–3.1, p < 0.001). The SF12 data
also showed that the nurse group had the greatest
improvement (140.7 (96.5–184.8) p < 0.001). 'GP' drug
costs (per patient per week) rose by £19.30 and 'GNP'
group fell by £24.30 over the study period with a signifi-
cant difference at 6 months (£39.6 (£24.2–£55.1) p <
0.001).
Seven patients in each arm had a positive H. pylori test and
received eradication therapy. The same number of
patients (3) in each group had further tests. In the 'GP'
group, 2 patients recalled having a urea breath test to con-
firm eradication success and 1 had abdominal ultra sound
for epigastric pain; all had negative findings. Three
patients in the 'nurse' group had 24-hour pH manometery
studies, for volume reflux and severe GORD was con-
firmed. Two patients opted for surgical intervention. Cri-
teria for further investigation by the nurse were according
to routine clinical protocol for patients with severe and/or
treatment resistant dyspeptic symptoms.
Of the nine domains in the Gladys questionnaire (see
Table 3), four showed improvement in the 'GNP' group:
reduced episodes of dyspepsia (p = 0.003), less dyspepsia
interfering with normal activities (p < 0.001), lower doc-
tor visits (though this would be anticipated due to the
design), and less prescribed UHDs (p = 0.001); no signif-
icant differences were seen in the remaining five. Seven
out of twelve domains in SF12 (see Table 4) showed sig-
nificant improvement in the 'GNP' group.
Patterns of drug use
The baseline UHD use was well matched (see Table 1)
between the 2 groups. Over the 6 month follow-up period
the GNP group consumed less months of 'full-dose PPI'
medication 1.5(0.8–2.1) p < 0.0001 and more had 'no
treatment' 1.7(0.9–2.4) p < 0.001. There were similar
months of 'half-dose PPIs and H2RAs'used in both groups
(see Table 5).
Discussion
This is the first randomised controlled trial to investigate
the effectiveness of nurse-led dyspepsia management
compared to usual GP follow-up. A robust reproducible
intervention to control symptoms and minimise medica-
tion was achieved by providing patients with appropriate
information after OGD. The main findings were a signifi-
cant reduction in symptom severity, an improvement in
health related quality of life, and reduced anti-ulcer drug
use and costs in the nurse-led group.
This trial followed established design principles with con-
cealed allocation, minimal loss to follow-up, blinding of
assessment and use of validated assessment instruments.
It was a pragmatic study, which compared different pro-
fessionals in different locations comparing current prac-
tice. The main limitation was the use of a single centre
with only six-month follow-up. Longer follow-up would
allow assessment of sustainability of the intervention, and
This figure shows the number of patients approached,  recruited, randomised to follow-up and seen by the Gas- trointestinal nurse practitioner and GPs in both cohorts Figure 1
This figure shows the number of patients 
approached, recruited, randomised to follow-up and 
seen by the Gastrointestinal nurse practitioner and 
GPs in both cohorts.
Recruited & consented (196) 
Eligible (175)  Not eligible (21) 
GP (86)  GNP (89) 
Withdrawn (4) Follow up (83):
   Seen by GP (40) 
   Not seen (43)
Withdrawn (3) Follow up (85): 
  Seen by GNP (78) 
  Not seen (7)
Follow up at 
month 6 (79) 
Follow up at 
month 6 (81)
Lost (4) Lost (4) 
Randomised
Blinded
assessment
Approached (199)BMC Gastroenterology 2009, 9:12 http://www.biomedcentral.com/1471-230X/9/12
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increasing the number of centres would enhance general-
isibility. A potential limitation was the lack of distinction
between different diagnostic groups; with mixing of non-
ulcer type and reflux-type symptoms though appropriate
lifestyle advice was provided based on predominant
symptoms. We did not undertake full economic costing
but rather focused on drug costs as the major component.
The overall cost-effectiveness of this strategy need further
evaluation taking into account all cost elements i.e. clini-
cians' time, additional investigation, surgical intervention
and administrative support.
Previous studies have shown the beneficial effect of gas-
troscopy on patients' symptoms [8-10]. The outcome of
this study shows that the additional interventions in the
nurse-led clinic had added benefit; by reducing UHD costs
on the background of improved symptoms and well
being. The major differences between this and other upper
GI nurse-led studies include the use of valid end-points,
randomised design and estimation of the impact on drug
cost [11-13]. This study demonstrates that investigation is
not the end point of dyspepsia management; rather it pro-
vides clinicians with the means to formulate a personal-
ised treatment plan and the importance of explanation,
counselling and patient empowerment in managing their
illness.
A contributory factor to the greater effectiveness of nurse-
led care might have been the low attendance rate (47%)
of patients to see their GPs after endoscopy, compared to
the almost universal attendance at the nurse clinic. This
emphasizes the need for appropriate advice even if
patients are found to have minor or normal findings.
Patient perspectives on the nurse clinic were very positive.
The structured approach supported by locally devised life-
style leaflets to reinforce this advice, may have motivated
patients to self-care more effectively e.g. avoid late meals,
reduce portion size, smoking, alcohol and caffeine and
may have contributed to the outcome differences [14-18].
The cost of drugs used had increased by approximately
one third at six months review in the 'GP' group. This
increase was consistent with the Gladys questionnaire in
'over-the-counter' drug use. Dyspepsia is a symptoms-
complex disorder and although UHDs may be effective in
controlling acid-related symptoms, their use for non-acid
related disorders are inadequate [19-22]. Thus with advice
on healthy lifestyle and stress management, non-acid
related symptoms could be controlled more effectively,
leading to UHD reduction. In a wider context, nurse-led
follow-up could augment medical care, improve general
health and release doctors' time to focus on more complex
cases. This may be an important strategy as more diagnos-
tic endoscopy is carried out in primary care, though the
effectiveness of nurse-led care within the primary care set-
ting would need to be tested. The study did not examine
GPs' satisfaction with nurse-managed care, as it has been
established in other specialist nurse-led services [23-25].
It is conceivable that the strategy could be transferable to
other specialist areas with less complex, high volume ill-
nesses, e.g. irritable bowel syndrome, where time and
counselling skills are required in addition to support from
both medical and nursing professional bodies [26-29].
Furthermore, this is an agenda in the NHS reform of the
care of patients with chronic illness in the community
[30].
Conclusion
In conclusion, follow-up management of dyspepsia after
direct access gastroscopy is variable. It can be standardised
involving an experienced GNP, with sufficient time to give
practical advice, which can empower patient to self-care
effectively. This can lead to substantial health gains and
Table 2: Comparison of key outcomes at 6 month follow-up between the 'GP' and 'GNP' groups.
Unadjusted Adjusted*
GP
(n = 86)
Nurse
(n = 89)
GP -- GNP GP -- GNP
Mean score (SD) Mean difference
(95% CI)
p-value Mean difference
(95% CI)
p-value
SF 12 634.8
(195.8)
754.5
(138.6)
-119.7 (-170.6, -68.9) < 0.001 -140.7 (-184.8, -96.5) < 0.001
Gladys score 7.2
(3.1)
4.9
(2.9)
2.3 (1.4, 3.2) < 0.001 2.3 (1.4, 3.1) < 0.001
UHD costs (£) 71.7
(63.1)
35.5
(48.8)
36.2 (19.3, 53.1) < 0.001 39.6 (24.2, 55.1) < 0.001
* Adjusted for baseline level using ANOVA.BMC Gastroenterology 2009, 9:12 http://www.biomedcentral.com/1471-230X/9/12
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reductions in drug costs in the community. This approach
needs to be tested in other centres.
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Table 3: Comparison of individual Gladys questionnaire responses at 6 month follow-up.
Treatment group p value
GP GNP
Health limited social activities All of the time 0 (0) 0 (0) 0.225†
Most of the time 1 (1) 2 (3)
A good bit of the time 1 (1) 0 (0)
Some of the time 5 (6) 2 (3)
A little of the time 6 (8) 4 (5)
None of the time 66 (84) 73 (90)
Over the last 6 months how frequent were indigestion symptoms Never 7 (9) 10 (12) 0.003†
1 or 2 days 9 (11) 21 (26)
1 day per month 15 (19) 16 (20)
1 day per week 22 (28) 22 (27)
50% of days 12 (15) 7 (9)
Most days 14 (18) 5 (6)
Did indigestion interfere with normal activities Never 21 (27) 44 (54) <0.001†
Sometimes 45 (57) 34 (42)
Regularly 13 (17) 3 (4)
Days off work due to indigestion in 6 months None 74 (94) 79 (98) 0.236†
1–7 days 3 (4) 1 (1)
More than 7 days 2 (3) 1 (1)
Frequency of attending a doctor in 6 months None 63 (80) 77 (95) 0.003†
Once 6 (8) 2 (3)
Twice or more 10 (13) 2 (3)
GP home visits due to indigestion in 6 months None 79 (100) 81 (100) 1.000†
Once 0 (0) 0 (0)
Twice or more 0 (0) 0 (0)
Number of tests for indigestion in 6 months None 76 (96) 78 (96) 0.975†
Once 3 (4) 3 (4)
Twice or more 0 (0) 0 (0)
Use of self-obtained medication in 6 months Never 38 (48) 47 (58) 0.047†
Less than 1/week 19 (24) 26 (32)
More than 1/week 22 (28) 8 (10)
Use of prescribed drugs in 6 months Never 15 (19) 31 (38) 0.001†
1 month or less 8 (10) 14 (17)
1 to 3 months 8 (10) 8 (10)
More than 3 months 48 (61) 28 (35)
† P value from Mann-Whitney test.
Figures are number (%).BMC Gastroenterology 2009, 9:12 http://www.biomedcentral.com/1471-230X/9/12
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Table 4: Comparison of individual SF12 questions at 6 months follow-up.
Treatment group p value
GP GNP
General health Excellent 1 (1) 7 (9) < 0.001†
Very good 8 (10) 32 (40)
Good 33 (42) 26 (32)
Fair 35 (44) 15 (19)
Poor 2 (3) 1 (1)
Health limited – Moderate activities Yes, limited a lot 3 (4) 1 (1) 0.261†
Yes, limited a little 15 (19) 12 (15)
No, not limited at all 61 (77) 68 (84)
Health limited – Climbing several flights of stairs Yes, limited a lot 6 (8) 2 (3) 0.021†
Yes, limited a little 21 (27) 13 (16)
No, not limited at all 52 (66) 66 (82)
Accomplished less than you would like in 4 weeks Yes 27 (34) 8 (10) < 0.001‡
No 52 (66) 73 (90)
Were limited in the kind of work or other activities in 4 weeks Yes 22 (28) 7 (9) 0.002‡
No 57 (72) 74 (91)
Accomplished less than you would like Yes
No
22 (28)
57 (72)
6 (7)
75 (93)
0.001‡
Didn't do work or other activities as carefully as usual Yes 15 (19) 4 (5) 0.006‡
No 64 (81) 77 (95)
Pain interfering with normal work in 4 weeks Not at all 31 (39) 42 (52) 0.023†
A little bit 24 (30) 28 (35)
Moderately 8 (10) 3 (4)
Quite a bit 11 (14) 8 (10)
Extremely 5 (60) 0 (0)
Felt calm and peaceful All of the time 5 (6) 5 (6) 0.024†
Most of the time 17 (22) 31 (38)
A good bit of the time 7 (9) 4 (5)
Some of the time 35 (44) 36 (44)
A little of the time 11 (14) 2 (3)
None of the time 4 (5) 3 (4)
Had a lot of energy All of the time 1 (1) 3 (4) 0.002†
Most of the time 13 (17) 24 (30)
A good bit of the time 7 (9) 12 (15)
Some of the time 33 (42) 29 (36)
A little of the time 14 (18) 10 (12)
None of the time 11 (14) 3 (4)
Felt downhearted and low All of the time 1 (1) 0 (0) 0.001†
Most of the time 6 (8) 1 (1)
A good bit of the time 6 (8) 2 (3)
Some of the time 30 (38) 24 (30)
A little of the time 18 (23) 20 (25)
None of the time 18 (23) 34 (42)
† P value from Mann-Whitney test.
‡P value from Chi-square test.
Figures are number (%).BMC Gastroenterology 2009, 9:12 http://www.biomedcentral.com/1471-230X/9/12
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Table 5: Comparison of monthly UHD use at 6 month follow-up between 'GP' and 'GNP' groups.
Unadjusted Adjusted*
GP
(n = 86)
GNP
(n = 89)
GP -- GNP GP -- GNP
Drug pattern in months Mean score (SD) Mean difference
(95% CI)
p-value Mean difference
(95% CI)
p-value
Full dose PPI  2.0 (2.7) 0.6 (1.7) 1.4 (0.8, 2.1) < 0.001 1.5 (0.8, 2.1) < 0.001
Half dose PPIs 1.5 (2.4) 1.4 (2.3) 0.0 (-0.7, 0.7) 0.942 0.1 (-0.5, 0.8) 0.702
No treatment 2.5 (2.7) 4.0 (2.5) -1.5 (-2.2, -0.7) < 0.001 -1.7 (-2.4, -0.9) < 0.001
* Adjusted for baseline level.
† Including all H2RAs.